Inspire Medical Systems, Inc.
$1.63B- Market cap
- $1.82B
- Debt
- +$112.36M
- Cash
- −$308.27M
Capital structure 94% equity / 6% debt · EV / Revenue 1.79x · EV / EBITDA 24.73x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: INSP stock price vs ANDE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANDE's multiple
Needs ANDE P/E.
Implied fair value · at INSP's multiple
Needs INSP P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INSP FY 2025 (ended Dec 31, 2025) · ANDE FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 1.79x · EV / EBITDA 24.73x
Capital structure 79% equity / 21% debt · EV / Revenue 0.26x · EV / EBITDA 15.94x
ANDE carries the larger enterprise value at $2.88B against $1.63B; ANDE trades on the lower EV / Revenue multiple (0.26x vs 1.79x); ANDE on the lower EV / EBITDA (15.94x vs 24.73x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Inspire Medical Systems, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ANDERSONS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.14x
0.50x
Net debt / EBITDA
Leverage against operating earnings
-2.98x
2.91x
Cash and equivalents
Liquid reserves on the balance sheet
$308.27M
$98.28M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BOSTON SCIENTIFIC CORP
INSP vs BSX
Medtronic plc
INSP vs MDT
ABBOTT LABORATORIES
INSP vs ABT
JOHNSON & JOHNSON
INSP vs JNJ
LivaNova PLC
INSP vs LIVN
Archer-Daniels-Midland Co
INSP vs ADM
CAL-MAINE FOODS INC
INSP vs CALM
CF Industries Holdings, Inc.
INSP vs CF
Nutrien Ltd.
INSP vs NTR
$112.36M
$623.39M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.